Calcipotriene
- Atc Codes:D05AX02
- CAS Codes:112965-21-6
- PHARMGKB ID:112965-21-6
Table of contents
- Brand Names
- Drug Combinations
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Unlabeled Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Caution and personalized dose adjustment in patients with the following genotypes
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Psorcutan; Belgium: Daivonex; Bulgaria: Daivonex; Cyprus: Dovonex; Czech Republic: Daivonex; Denmark: Daivonex; Estonia: Daivonex; Finland: Daivonex; France: Daivonex; Germany: Calcipotriol, Daivonex, Psorcutan; Greece: Calcipotriol, Cipocal, Dopotril, Dovonex, F-Psorin, Fenipsorian, Psoraffect; Hungary: Daivonex, Psoriderm; Ireland: Dovonex; Italy: Daivonex, Psorcutan; Latvia: Daivonex; Malta: Daivonex; Netherlands: Calcipotriol, Daivonex; Poland: Calcipotriol, Daivonex, Sorel; Portugal: Daivonex; Romania: Daivonex; Slovakia: Daivonex; Slovenia: Daivonex, Sorel; Spain: Daivonex; Sweden: Calcipotriol, Daivonex; UK: Calcipotriol, Dovonex.
North America
Canada: Dovonex; USA: Dovonex, Sorilux.
Latin America
Argentina: Daivonex; Brazil: Daivonex; Mexico: Daivonex, Eukadar.
Asia
Japan: Dovonex.
Drug combinations
Calcipotriene and Betamethasone
Chemistry
Calcipotriene: C~27~H~40~O~3~. Mw: 412.60. (1) 9,10-Secochola-5,7,10(19),22-tetraene-1,3,24-triol, 24-cyclopropyl-, (1α,3β,5Z,7E,22E,24S)-; (2)(5Z,7E,22E,24S)-24-Cyclopropyl-9,10-secochola-5,7,10(19),22-tetraene-1α,3β,24-triol. CAS-112965-21-6 (1992).
Pharmacologic Category
Skin and Mucous Membrane Agents, Miscellaneous; Vitamin D Analog. (ATC-Code: D05AX02).
Mechanism of action
Synthetic vitamin D~3~ analog which regulates skin cell production and proliferation.
Therapeutic use
Calcipotriene ointment and cream are used topically in the management of plaque psoriasis, and calcipotriene solution is used topically for the management of chronic, moderately severe psoriasis of the scalp.
Pregnancy and lactiation implications
Teratogenic effects observed in animal studies. There are no adequate studies in pregnant women. Use with caution during lactation.
Unlabeled use
Vitiligo.
Contraindications
Hypersensitivity to calcipotriene or any component of the formulation. Hypercalcemia or evidence of vitamin D toxicity. Use on the face. Acute psoriatic eruptions (scalp solution).
Warnings and precautions
May cause transient increases in serum calcium (reversible). May cause irritation of lesions and surrounding uninvolved skin. For external use only (not for ophthalmic, oral, or intravaginal use). Avoid or limit excessive exposure to natural or artificial sunlight, or phototherapy.